Geron is a biopharmaceutical company focused on development and commercialization of therapies in hematologic malignancies. Geron aims to deliver on our mission of changing lives by changing the course of blood cancers.
Geron is a late-stage biopharmaceutical company pursuing discoveries with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science that may alter the underlying drivers of disease. The United States Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2024 for Geron’s New Drug Application (NDA) for imetelstat.